Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
- The CLEAR Trial Investigators
- Memorial Sloan-Kettering Cancer Center
- University of Bari
- University of Pavia
- Kyushu University
- Royal Free London NHS Foundation Trust
- University of Duisburg-Essen
- Texas Oncology
- P.A. Herzen Moscow Oncological Research Institute
- Yonsei University
- University of Miami
- Queensland University of Technology
- McMaster University
- IRCCS Istituto scientifico romagnolo per lo studio e la cura dei tumori - Meldola (FC)
- University Hospital Olomouc
- The Catholic University of Korea
- Macquarie University
- Hospital Universitario Reina Sofía
- State Institution of Healthcare Regional Clinical Oncology Dispensary
- Russian Academy of Medical Sciences - N.N. Blokhin Russian Cancer Research Center
- Hospital Ramon y Cajal
- State Budgetary Health Care Institution Novosibirsk Regional Clinical Oncology Dispensary
- Prevoljskiy Region Medical Centre
- Western University
- Hospital de La Santa Creu I Sant Pau
- Seoul National University
- IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano
- Tokyo Women's Medical University
- Western Health
- Klinikum Stuttgart
- Medical University of Vienna
- Merck
- Eisai Co., Ltd.
- Dana-Farber Cancer Institute
Research output: Contribution to journal › Article › peer-review
123
Scopus
citations